---
schema_version: "secwatch.filing_event.v1"
accession: "0000885590-26-000008"
form_type: "8-K"
ticker: "BHC"
cik: "0000885590"
company_name: "Bausch Health Companies Inc."
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:38:26.355509+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Bausch Health issues press release on Phase 3 RED-C trial; no details in filing text

## Summary
- Press release announces results of global Phase 3 RED-C program for amorphous-rifaximin in liver cirrhosis.
- Trial evaluated primary prevention of hepatic encephalopathy; specific endpoint outcomes not provided in filing summary.
- Filing includes only the 8-K body; the attached Exhibit 99.1 text was not included for analysis.
- Item 7.01 Regulation FD disclosure; information is furnished, not filed, per standard practice.

## SEC filing metadata
- accession: 0000885590-26-000008
- form_type: 8-K
- ticker: BHC
- cik: 0000885590
- company_name: Bausch Health Companies Inc.
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885590/000088559026000008/0000885590-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885590/000088559026000008/bhc-20260123.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885590-26-000008
- JSON: https://secwatch.observer/filing/0000885590-26-000008.json
- Plain text: https://secwatch.observer/filing/0000885590-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.